Form 4: Phathom Officer Sells Shares for Tax Obligation
Insider Transaction Report
Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, disposed of 230 common shares to cover tax withholding obligations.
Summary
- Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc. (PHAT), disposed of 230 shares of common stock.
- The transaction occurred on December 18, 2025, at a price of $16.28 per share.
- These shares were surrendered to the Issuer to satisfy tax withholding obligations related to restricted stock units.
- Following this transaction, Mr. Breedlove directly beneficially owns 47,844 shares of common stock.
- Additionally, Mr. Breedlove indirectly beneficially owns 6,945.4 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The transaction is a neutral event, representing a routine tax withholding related to equity compensation, with no positive or negative implications for the company's operational or financial performance.
Future Outlook
The filing does not contain any forward-looking statements or guidance.
Industry Context
This is a routine insider transaction for tax withholding purposes, common across all industries when restricted stock units vest. It does not reflect broader industry trends or competitive positioning.
Comparison to Industry Standards
- The disposition of shares to cover tax obligations upon the vesting of restricted stock units is a standard practice for executives across publicly traded companies, including those in the pharmaceutical sector.
- This type of transaction is not indicative of a change in investment sentiment but rather a compliance requirement.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, small-scale transaction for tax purposes by an officer, not a discretionary sale based on company outlook.
- Employees: No direct impact on employees.
Key Dates
| Date | Description |
|---|---|
| 12/18/2025 | Date of transaction where shares were disposed of for tax withholding. |
| 12/19/2025 | Date the Form 4 was signed by Robert Charles Breedlove. |
Keywords
Phathom Pharmaceuticals, PHAT, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Officer Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.